Estimating the Cost Effectiveness of Ramipril used for Specific Clinical Indications: Comparing the Outcomes in Four Clinical Trials with a Common Economic Model

Author： Grover Steven A.   Coupal Louis   Lowensteyn Ilka  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.7, Iss.6, 2007-01, pp. : 441-448

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

On Cost Effectiveness and Sample Size in Clinical Trials

By Augustinus A.M. Hart   Marcel G.W. Dijkgraaf  

PharmacoEconomics, Vol. 22, Iss. 10, 2004-01 ,pp. : 685-688

Adis International

Access to resources Recommend Favorite

Ramipril: clinical, economic advantages in diabetes, stable angina

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 413, 2003-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Ramipril: clinical, economic advantages in diabetes, stable angina

By  

Inpharma, Vol. 1, Iss. 1388, 2003-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

On Cost Effectiveness and Sample Size in Clinical Trials. The Author's Reply

By Martin E. Backhouse  

PharmacoEconomics, Vol. 22, Iss. 10, 2004-01 ,pp. : 688-689

Adis International

Access to resources Recommend Favorite

Comparing Methods of Data Synthesis: Re-Estimating Parameters of an Existing Probabilistic Cost-Effectiveness Model

By Oppe Mark   Al Maiwenn   Mölken Maureen Rutten-van  

PharmacoEconomics, Vol. 29, Iss. 3, 2011-03 ,pp. : 239-250

Adis International

Access to resources Recommend Favorite